Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954757 | 0.71 | TAAR1 (0.56) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL1679282 | 0.71 | TAAR1 (0.64) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL28277587 | 0.69 | TAAR1 (0.67) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL27554365 | 0.68 | TAAR1 (0.65) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL13372830 | 0.68 | TAAR1 (0.80) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL954645 | 0.67 | TAAR1 (0.65) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL29748356 | 0.67 | TAAR1 (0.59) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL28062277 | 0.66 | TAAR1 (0.58) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL11295562 | 0.66 | TAAR1 (0.69) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL1509682 | 0.66 | TAAR1 (0.67) | TAAR1ADRA2AADRA2BADRA2CHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1248615-B1 | THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON INC (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1785134-A2 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ALTEON, INC. (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060014781-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-6960605-B2 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ALTEON, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1248615-A4 | THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON INC (US) | 2004-08-04 | — | — | EP | disclosed |
| CN-1426303-A | Thiazole, imidazole and oxazole compounds and treatment of diseases associated with protein aging | ALTEON INC (US) | 2003-06-25 | — | — | CN | disclosed |
| EP-1248615-A1 | THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | Alteon, Inc. (US) | 2002-10-16 | — | — | EP | disclosed |
| US-20020022622-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2001052847-A1 | THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022622-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ABAT, NDUFAB1, HSPE1 | TAAR1 2045/4885ADRA2A 3730/4885ADRA2B 4096/4885 |
| US-20060014781-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ABAT, HSPE1, TXN2 | TAAR1 2836/4885ADRA2A 3849/4885ADRA2B 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.